PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Human Molecular Genetics

• Publication date

  2015-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/hmg/ddu587PMID 25432537PMCID PMC4381760
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ER–mitochondria associations are regulated by the VAPB–PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43

  2014cited by this paper
• Glial cells in amyotrophic lateral sclerosis.

  2014cited by this paper
• Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.

  2014cited by this paper
• An atlas of genetic influences on human blood metabolites

  2014cited by this paper
• New Insights into the PPARγ Agonists for the Treatment of Diabetic Nephropathy

  2014cited by this paper
• Genetically altering organismal metabolism by leptin-deficiency benefits a mouse model of amyotrophic lateral sclerosis.

  2014cited by this paper
• Metabolic Therapy with Deanna Protocol Supplementation Delays Disease Progression and Extends Survival in Amyotrophic Lateral Sclerosis (ALS) Mouse Model

  2014cited by this paper
• Endoplasmic reticulum stress is accompanied by activation of NF-κB in amyotrophic lateral sclerosis.

  2014cited by this paper
• The ER mitochondria calcium cycle and ER stress response as therapeutic targets in amyotrophic lateral sclerosis

  2014cited by this paper
• Effects of diabetes mellitus on amyotrophic lateral sclerosis: a systematic review

  2014cited by this paper
• Protein aggregation in amyotrophic lateral sclerosis

  2013cited by this paper
• State of play in amyotrophic lateral sclerosis genetics

  2013cited by this paper
• Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD–ALS spectrum disorders

  2013cited by this paper
• Converging mechanisms in ALS and FTD: disrupted RNA and protein homeostasis.

  2013cited by this paper
• Pioglitazone leads to an inactivation and disassembly of complex I of the mitochondrial respiratory chain

  2013cited by this paper
• Motor neurons and glia exhibit specific individualized responses to TDP-43 expression in a Drosophila model of amyotrophic lateral sclerosis

  2013cited by this paper
• Amyotrophic lateral sclerosis: Problems and prospects

  2013cited by this paper
• More than a bystander: the contributions of intrinsic skeletal muscle defects in motor neuron diseases

  2013cited by this paper
• Targeting peroxisome proliferator-activated receptor gamma for generation of antidiabetic drug.

  2013cited by this paper
• A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis

  2012cited by this paper
• The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function

  2012cited by this paper
• The tip of the iceberg: RNA-binding proteins with prion-like domains in neurodegenerative disease.

  2012cited by this paper
• Pioglitazone

  2012cited by this paper
• Biochemical alterations associated with ALS

  2012cited by this paper
• Mutations in the Profilin 1 Gene Cause Familial Amyotrophic Lateral Sclerosis

  2012cited by this paper
• A Pilot Trial of Pioglitazone HCl and Tretinoin in ALS: Cerebrospinal Fluid Biomarkers to Monitor Drug Efficacy and Predict Rate of Disease Progression

  2012cited by this paper
• Characterising the RNA targets and position-dependent splicing regulation by TDP-43; implications for neurodegenerative diseases

  2011cited by this paper
• The ALS-associated proteins FUS and TDP-43 function together to affect Drosophila locomotion and life span.

  2011cited by this paper
• Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration

  2011cited by this paper
• Long pre-mRNA depletion and RNA missplicing contribute to neuronal vulnerability from loss of TDP-43

  2011cited by this paper
• Wild-type and A315T mutant TDP-43 exert differential neurotoxicity in a Drosophila model of ALS.

  2011cited by this paper
• FUS and TARDBP but Not SOD1 Interact in Genetic Models of Amyotrophic Lateral Sclerosis

  2011cited by this paper
• A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD.

  2011cited by this paper
• Glial Cells in Amyotrophic Lateral Sclerosis

  2011cited by this paper
• RNA-binding proteins and RNA metabolism: a new scenario in the pathogenesis of Amyotrophic lateral sclerosis.

  2011cited by this paper
• A Drosophila model of FUS-related neurodegeneration reveals genetic interaction between FUS and TDP-43.

  2011cited by this paper
• A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS

  2010cited by this paper
• ALS disease onset may occur later in patients with pre‐morbid diabetes mellitus

  2010cited by this paper
• TDP-43-Mediated Neuron Loss In Vivo Requires RNA-Binding Activity

  2010cited by this paper
• A Drosophila model for TDP-43 proteinopathy

  2010cited by this paper
• Current hypotheses for the underlying biology of amyotrophic lateral sclerosis

  2009cited by this paper
• Rethinking ALS: the FUS about TDP-43.

  2009cited by this paper
• Mutations in the FUS/TLS Gene on Chromosome 16 Cause Familial Amyotrophic Lateral Sclerosis

  2009cited by this paper
• Hypermetabolism in ALS patients: an early and persistent phenomenon

  2009cited by this paper
• TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis

  2008cited by this paper
• TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis.

  2008cited by this paper
• Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.

  2008influential reference
• Design, power, and interpretation of studies in the standard murine model of ALS

  2008cited by this paper
• Novel Mutations in TARDBP (TDP-43) in Patients with Familial Amyotrophic Lateral Sclerosis

  2008cited by this paper
• A Drosophila Model for Amyotrophic Lateral Sclerosis Reveals Motor Neuron Damage by Human SOD1

  2008cited by this paper
• TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis

  2008cited by this paper
• Ischemic Preconditioning Reveals that GLT1/EAAT2 Glutamate Transporter is a Novel PPARγ Target Gene Involved in Neuroprotection

  2007cited by this paper
• Lost in translation: Treatment trials in the SOD1 mouse and in human ALS

  2007cited by this paper
• A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis

  2006cited by this paper
• Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis

  2006cited by this paper
• Nuclear receptors — a perspective from Drosophila

  2005cited by this paper
• The Oral Antidiabetic Pioglitazone Protects from Neurodegeneration and Amyotrophic Lateral Sclerosis-Like Symptoms in Superoxide Dismutase-G93A Transgenic Mice

  2005cited by this paper
• Peroxisome proliferator-activated receptor-gamma agonist extends survival in transgenic mouse model of amyotrophic lateral sclerosis

  2005cited by this paper
• The Peroxisome Proliferator-activated Receptor-γ Regulates Murine Pyruvate Carboxylase Gene Expression in Vivo and in Vitro*

  2005cited by this paper
• Therapeutic roles of peroxisome proliferator-activated receptor agonists.

  2005cited by this paper
• The peroxisome proliferator-activated receptor-gamma regulates murine pyruvate carboxylase gene expression in vivo and in vitro.

  2005cited by this paper
• Evidence for defective energy homeostasis in amyotrophic lateral sclerosis: benefit of a high-energy diet in a transgenic mouse model.

  2004cited by this paper
• Identification of a novel mitochondrial protein ("mitoNEET") cross-linked specifically by a thiazolidinedione photoprobe.

  2004cited by this paper
• Statistical significance for genomewide studies

  2003cited by this paper
• “True” sporadic ALS associated with a novel SOD‐1 mutation

  2002cited by this paper
• Characterization and Functional Implications of the RNA Binding Properties of Nuclear Factor TDP-43, a Novel Splicing Regulator ofCFTR Exon 9*

  2001cited by this paper
• ALS-linked SOD1 mutant G85R mediates damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions.

  1997cited by this paper
• Research in Health Care

  1996cited by this paper
• Regulation of synapse structure and function by the Drosophila tumor suppressor gene dlg.

  1996cited by this paper
• Distinct expression patterns detected within individual tissues by the GAL4 enhancer trap technique.

  1996cited by this paper
• The Peroxisome Proliferator‐activated Receptors: Ligands and Activators a

  1996cited by this paper
• Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs

  1995cited by this paper
• Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation.

  1994cited by this paper
• Targeted gene expression as a means of altering cell fates and generating dominant phenotypes.

  1993cited by this paper
• Cellular Neuroscience Mini Review Article the Role of Oxidative Stress in Degeneration of the Neuromuscular Junction in Amyotrophic Lateral Sclerosis

  year unknowncited by this paper

• Suppression of har-1/CHCHD10 phenotypes for ALS-FTD therapy discovery

  2025cites this paper
• Hepatocyte-like cells die via steroid hormone and nuclear receptor E75-mediated apoptosis

  2025cites this paper
• Neuronal fatty acid-binding protein enhances autophagy and suppresses amyloid-β pathology in a Drosophila model of Alzheimer’s disease

  2024cites this paper
• Promising animal models for amyotrophic lateral sclerosis drug discovery: a comprehensive update

  2024cites this paper
• Drug Screening and Validation Targeting TDP-43 Proteinopathy for Amyotrophic Lateral Sclerosis

  2024influential citation
• Prospects of antidiabetic drugs in the treatment of neurodegenerative disease

  2024cites this paper
• Therapeutic potential of simvastatin in ALS: Enhanced axonal integrity and motor neuron survival through Apoa4 and Alb modulation

  2024cites this paper
• A Novel Drosophila-based Drug Repurposing Platform Identified Fingolimod As a Potential Therapeutic for TDP-43 Proteinopathy

  2023cites this paper
• Steroid hormone regulation of innate immunity in Drosophila melanogaster

  2023cites this paper
• A nerve-wracking buzz: lessons from Drosophila models of peripheral neuropathy and axon degeneration

  2023cites this paper
• Key Disease Mechanisms Linked to Amyotrophic Lateral Sclerosis in Spinal Cord Motor Neurons

  2022cites this paper
• A chemogenomic approach is required for effective treatment of amyotrophic lateral sclerosis

  2022cites this paper
• TDP-43 Proteinopathy Causes Broad Metabolic Alterations including TCA Cycle Intermediates and Dopamine Levels in Drosophila Models of ALS

  2022cites this paper
• RNA interference-mediated silencing of retinoid x receptor causes reproductive failure in the sea lice Caligus rogercresseyi

  2022cites this paper
• Downstream Effects of Mutations in SOD1 and TARDBP Converge on Gene Expression Impairment in Patient-Derived Motor Neurons

  2022cites this paper
• Fungal consortium of two Beauveria bassiana strains increases their virulence, growth, and resistance to stress: A metabolomic approach

  2022cites this paper
• Altered Bioenergetics and Metabolic Homeostasis in Amyotrophic Lateral Sclerosis

  2022cites this paper
• The Impact of Mitochondrial Dysfunction in Amyotrophic Lateral Sclerosis

  2022cites this paper
• Rational design, molecular docking, dynamic simulation, synthesis, PPAR-γ competitive binding and transcription analysis of novel Glitazones

  2022cites this paper
• Animal Models of Neurodegenerative Disease: Recent Advances in Fly Highlight Innovative Approaches to Drug Discovery

  2022cites this paper
• An obesogenic feedforward loop involving PPARγ, acyl-CoA binding protein and GABAA receptor

  2022cites this paper
• Genetic variation of macronutrient tolerance in Drosophila melanogaster

  2022cites this paper
• The Nitric Oxide Donor, S-Nitrosoglutathione, Rescues Peroxisome Number and Activity Defects in PEX1G843D Mild Zellweger Syndrome Fibroblasts

  2021influential citation
• Role of Phytoconstituents as PPAR Agonists: Implications for Neurodegenerative Disorders

  2021influential citation
• Glitazone Treatment Rescues Phenotypic Deficits in a Fly Model of Gaucher/Parkinson’s Disease

  2021cites this paper
• Ketogenic diet reduces early mortality following traumatic brain injury in Drosophila via the PPARγ ortholog Eip75B

  2021cites this paper
• Thioridazine reverts the phenotype in cellular and Drosophila models of amyotrophic lateral sclerosis by enhancing TDP-43 aggregate clearance.

  2021cites this paper
• Involvement of Astrocytes and microRNA Dysregulation in Neurodegenerative Diseases: From Pathogenesis to Therapeutic Potential

  2021cites this paper
• The overexpression of TDP-43 in astrocytes causes neurodegeneration via a PTP1B-mediated inflammatory response

  2020cites this paper
• Ecdysone steroid hormone remote controls intestinal stem cell fate decisions via the PPARγ-homolog Eip75B in Drosophila

  2020cites this paper
• IN VITRO AND IN VIVO MODELS OF AMYOTROPHIC LATERAL SCLEROSIS: AN UPDATED OVERVIEW.

  2020cites this paper
• Targeting TDP‐43 proteinopathy with drugs and drug‐like small molecules

  2020cites this paper
• Rosy Beginnings: Studying Peroxisomes in Drosophila

  2020cites this paper
• Why TDP-43? Why Not? Mechanisms of Metabolic Dysfunction in Amyotrophic Lateral Sclerosis

  2020cites this paper
• Amyotrophic Lateral Sclerosis: Proteins, Proteostasis, Prions, and Promises

  2020cites this paper
• The M1311V variant of ATP7A is associated with impaired trafficking and copper homeostasis in models of motor neuron disease

  2020cites this paper
• The Drosophila E78 nuclear receptor regulates dietary triglyceride uptake and systemic lipid levels

  2020cites this paper
• Nuclear Receptors as Therapeutic Targets for Neurodegenerative Diseases: Lost in Translation.

  2019cites this paper
• Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALS

  2019cites this paper
• TDP-43: A Key Therapeutic Target beyond Amyotrophic Lateral Sclerosis.

  2019cites this paper
• Naringenin Ameliorates Drosophila ReepA Hereditary Spastic Paraplegia-Linked Phenotypes

  2019cites this paper
• Small Molecule Targeting TDP-43’s RNA Recognition Motifs Reduces Locomotor Defects in a Drosophila Model of Amyotrophic Lateral Sclerosis (ALS)

  2019cites this paper
• Exploration and Development of PPAR Modulators in Health and Disease: An Update of Clinical Evidence

  2019cites this paper
• Targeting the Mitochondrial Pyruvate Carrier for Neuroprotection

  2019cites this paper
• A small molecule targeting TDP-43's RNA recognition motifs reduces locomotor defects in a Drosophila model of ALS.

  2019cites this paper
• Using Drosophila as a platform for drug discovery from natural products in Parkinson's disease.

  2019cites this paper
• Amyotrophic Lateral Sclerosis Model.

  2018cites this paper
• Medium-Chain Fatty Acids, Beta-Hydroxybutyric Acid and Genetic Modulation of the Carnitine Shuttle Are Protective in a Drosophila Model of ALS Based on TDP-43

  2018cites this paper
• High-throughput drug screens for amyotrophic lateral sclerosis drug discovery

  2018cites this paper
• Peroxisome proliferator-activated receptors (PPARs) as therapeutic target in neurodegenerative disorders.

  2017cites this paper
• TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD

  2017cites this paper
• Huaier Regulates Cell Fate by the Rescue of Disrupted Transcription Control in the Hippo Signaling Pathway

  2017cites this paper
• Metabolic Dysregulation in Amyotrophic Lateral Sclerosis: Challenges and Opportunities

  2017cites this paper
• Mitochondrial quality control in amyotrophic lateral sclerosis: towards a common pathway?

  2017cites this paper
• Metabolomic Studies in Drosophila

  2017cites this paper
• PPAR&bgr;/&dgr; activation protects against corticosterone‐induced ER stress in astrocytes by inhibiting the CpG hypermethylation of microRNA‐181a

  2017cites this paper
• PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease

  2016cites this paper
• Opposite Interplay between PPAR Gamma and Canonical Wnt/Beta-Catenin Pathway in Amyotrophic Lateral Sclerosis

  2016cites this paper
• Novel Neuroprotective Multicomponent Therapy for Amyotrophic Lateral Sclerosis Designed by Networked Systems

  2016cites this paper
• Modulating effect of losartan potassium on the mutagenicity and recombinogenicity of doxorubicin in somatic cells of Drosophila melanogaster.

  2016cites this paper
• Pathophysiological links between traumatic brain injury and post-traumatic headaches

  2016cites this paper
• ALS: A bucket of genes, environment, metabolism and unknown ingredients.

  2016cites this paper
• Metabolomics in amyotrophic lateral sclerosis: how far can it take us?

  2016cites this paper
• Simple animal models for amyotrophic lateral sclerosis drug discovery

  2016cites this paper
• The Role of TDP-43 in Alzheimer’s Disease

  2015cites this paper
• Drosophila as a model to study the role of glia in neurodegeneration

  2015cites this paper
• Rapamycin alleviates pathogenesis of a new Drosophila model of ALS-TDP

  2015cites this paper
• Pathophysiological links between traumatic brain injury and post-traumatic headaches [version 1; peer review: 3 approved]

  year unknowncites this paper